Literature DB >> 17611412

ALK is a novel dependence receptor: potential implications in development and cancer.

Michèle Allouche1.   

Abstract

ALK (anaplastic lymphoma kinase) is a transmembrane receptor tyrosine kinase, initially discovered as part of the NPM-ALK fusion protein, resulting from a chromosomal rearrangement frequently associated with anaplastic large cell lymphomas. The native ALK protein is normally expressed in the developing and, at a weaker level, adult nervous system. We recently demonstrated that ALK is a novel dependence receptor. As such, in the absence of ligand, the ALK receptor is kinase inactive and its expression results in enhanced apoptosis, whereas kinase activation, due to a ligand or constitutive as in NPM-ALK, decreases apoptosis. Unligated/kinase unactivated ALK receptor facilitates apoptosis via its own cleavage by caspases, a phenomenon allowing the exposure of a proapoptotic juxta-membrane intra-cellular domain. This review summarizes the biological significance of the ALK receptor in cancer and development, in perspective with its dependence receptor function. The dual function of ALK in the physiology of development is illustrated in the visual system of Drosophila. In this part of the nervous system, ALK in the presence of ligand appears essential for axonal guidance, whereas in the absence of ligand, ALK expression can lead to developmental neuronal apoptosis. ALK is also found expressed in neural crest-derived tumors such as human neuroblastomas or glioblastomas but its role is not fully elucidated. However, an excessive or constitutive ALK tyrosine kinase activation can lead to deregulation of cell proliferation and survival, therefore to human cancers such as lymphomas and inflammatory myofibroblastic tumors. Our observations could have important implications in the therapy of ALK-positive tumors harboring the chimeric or wild type ALK protein.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611412     DOI: 10.4161/cc.6.13.4433

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  15 in total

1.  Structural basis for the recognition of nucleophosmin-anaplastic lymphoma kinase oncoprotein by the phosphotyrosine binding domain of Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target-2.

Authors:  Seizo Koshiba; Hua Li; Yoko Motoda; Tadashi Tomizawa; Takuma Kasai; Naoya Tochio; Takashi Yabuki; Takushi Harada; Satoru Watanabe; Akiko Tanaka; Mikako Shirouzu; Takanori Kigawa; Tadashi Yamamoto; Shigeyuki Yokoyama
Journal:  J Struct Funct Genomics       Date:  2010-05-08

Review 2.  ALK-immunoreactive neoplasms.

Authors:  Parham Minoo; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

Review 3.  The roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development.

Authors:  Mayumi Higashi; Kohei Sakai; Shigehisa Fumino; Shigeyoshi Aoi; Taizo Furukawa; Tatsuro Tajiri
Journal:  Surg Today       Date:  2019-03-08       Impact factor: 2.549

4.  Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action.

Authors:  M Lorente; S Torres; M Salazar; A Carracedo; S Hernández-Tiedra; F Rodríguez-Fornés; E García-Taboada; B Meléndez; M Mollejo; Y Campos-Martín; S A Lakatosh; J Barcia; M Guzmán; G Velasco
Journal:  Cell Death Differ       Date:  2011-01-14       Impact factor: 15.828

5.  EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.

Authors:  Maria Paola Martelli; Gabriella Sozzi; Luis Hernandez; Valentina Pettirossi; Alba Navarro; Davide Conte; Patrizia Gasparini; Federica Perrone; Piergiorgio Modena; Ugo Pastorino; Antonino Carbone; Alessandra Fabbri; Angelo Sidoni; Shigeo Nakamura; Marcello Gambacorta; Pedro Luis Fernández; Jose Ramirez; John K C Chan; Walter Franco Grigioni; Elias Campo; Stefano A Pileri; Brunangelo Falini
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

6.  A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.

Authors:  Mark A Socinski; Jonathan Goldman; Iman El-Hariry; Marianna Koczywas; Vojo Vukovic; Leora Horn; Eugene Paschold; Ravi Salgia; Howard West; Lecia V Sequist; Philip Bonomi; Julie Brahmer; Lin-Chi Chen; Alan Sandler; Chandra P Belani; Timothy Webb; Harry Harper; Mark Huberman; Suresh Ramalingam; Kwok-Kin Wong; Florentina Teofilovici; Wei Guo; Geoffrey I Shapiro
Journal:  Clin Cancer Res       Date:  2013-04-03       Impact factor: 12.531

7.  An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.

Authors:  Marion Zillhardt; James G Christensen; Ernst Lengyel
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

8.  Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts.

Authors:  Juan Palacios-Moreno; Lauren Foltz; Ailan Guo; Matthew P Stokes; Emily D Kuehn; Lynn George; Michael Comb; Mark L Grimes
Journal:  PLoS Comput Biol       Date:  2015-04-17       Impact factor: 4.475

9.  Peptides derived from the dependence receptor ALK are proapoptotic for ALK-positive tumors.

Authors:  A Aubry; S Galiacy; L Ceccato; C Marchand; C Tricoire; F Lopez; R Bremner; C Racaud-Sultan; B Monsarrat; F Malecaze; M Allouche
Journal:  Cell Death Dis       Date:  2015-05-07       Impact factor: 8.469

Review 10.  Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas.

Authors:  Coralie Hoareau-Aveilla; Fabienne Meggetto
Journal:  Cancers (Basel)       Date:  2017-08-03       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.